Herein, we test the hypothesis by evaluating the relationships between the MBI scores, AD imaging biomarkers including brain burden of β-amyloid, brain burden of tau and neurodegeneration, and cognitive impairment in participants without dementia. The gene discussed is MAPT; the disease is Cognitive impairment.